Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 488

1.

Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.

Post MS, Christella M, Thomassen LG, van der Mooren MJ, van Baal WM, Rosing J, Kenemans P, Stehouwer CD.

Arterioscler Thromb Vasc Biol. 2003 Jun 1;23(6):1116-21. Epub 2003 May 1.

2.

Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study.

Hemelaar M, van der Mooren MJ, Mijatovic V, Bouman AA, Schijf CP, Kroeks MV, Franke HR, Kenemans P.

Menopause. 2003 Nov-Dec;10(6):550-8.

PMID:
14627865
3.

Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study.

Verhoeven MO, Hemelaar M, van der Mooren MJ, Kenemans P, Teerlink T.

J Intern Med. 2006 Feb;259(2):199-208.

4.

Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women.

Hemelaar M, Rosing J, Kenemans P, Thomassen MC, Braat DD, van der Mooren MJ.

Arterioscler Thromb Vasc Biol. 2006 Jul;26(7):1660-6. Epub 2006 Apr 27.

5.

Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study.

Post MS, van der Mooren MJ, van Baal WM, Blankenstein MA, Merkus HM, Kroeks MV, Franke HR, Kenemans P, Stehouwer CD.

Am J Obstet Gynecol. 2003 Nov;189(5):1221-7.

PMID:
14634544
6.

Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women.

Post MS, Rosing J, Van Der Mooren MJ, Zweegman S, Van Baal WM, Kenemans P, Stehouwer CD; Ageing Women' and the Institute for Cardiovascular Research-Vrije Universiteit (ICaR-VU).

Br J Haematol. 2002 Dec;119(4):1017-23.

PMID:
12472583
7.

A randomized placebo-controlled study of the effect of transdermal vs. oral estradiol with or without gestodene on homocysteine levels.

Smolders RG, van der Mooren MJ, Teerlink T, Merkus JM, Kroeks MV, Franke HR, Stehouwer CD, Kenemans P.

Fertil Steril. 2003 Feb;79(2):261-7.

PMID:
12568832
8.
9.

Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial.

Høibraaten E, Mowinckel MC, de Ronde H, Bertina RM, Sandset PM.

Br J Haematol. 2001 Nov;115(2):415-20.

PMID:
11703344
10.

Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.

Eilertsen AL, Liestøl S, Mowinckel MC, Hemker HC, Sandset PM.

Thromb Haemost. 2007 Jun;97(6):938-43.

PMID:
17549295
11.

Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.

Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M.

Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3071-8.

12.

Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.

Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, Virkamäki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Järvinen H.

Thromb Haemost. 2001 Apr;85(4):619-25.

PMID:
11341495
13.

Effects of transdermal and oral postmenopausal hormone therapy on vascular function: a randomized, placebo-controlled study in healthy postmenopausal women.

Hemelaar M, van der Mooren MJ, van Baal WM, Schalkwijk CG, Kenemans P, Stehouwer CD.

Menopause. 2005 Sep-Oct;12(5):526-35. Epub 2005 Sep 1.

PMID:
16145306
14.

Does the type of hormone replacement therapy affect lipoprotein (a), homocysteine, and C-reactive protein levels in postmenopausal women?

Bukowska H, Stanosz S, Zochowska E, Millo B, Sieja K, Chełstowski K, Naruszewicz M.

Metabolism. 2005 Jan;54(1):72-8.

PMID:
15562383
15.

Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women.

Decensi A, Omodei U, Robertson C, Bonanni B, Guerrieri-Gonzaga A, Ramazzotto F, Johansson H, Mora S, Sandri MT, Cazzaniga M, Franchi M, Pecorelli S.

Circulation. 2002 Sep 3;106(10):1224-8.

16.

Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial.

Oger E, Alhenc-Gelas M, Lacut K, Blouch MT, Roudaut N, Kerlan V, Collet M, Abgrall JF, Aiach M, Scarabin PY, Mottier D; SARAH Investigators.

Arterioscler Thromb Vasc Biol. 2003 Sep 1;23(9):1671-6. Epub 2003 Jul 17.

17.

Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.

Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Koster T, Bertina RM, Vandenbroucke JP.

Thromb Haemost. 1998 Sep;80(3):382-7.

PMID:
9759614
18.
19.

Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women.

Rabbani LE, Seminario NA, Sciacca RR, Chen HJ, Giardina EG.

J Am Coll Cardiol. 2002 Dec 4;40(11):1991-9.

20.

Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women: results from a randomized, controlled study.

Davis SR, Stuckey BG, Norman RJ, Papalia MA, Drillich A, Bell RJ.

Menopause. 2008 Nov-Dec;15(6):1065-9. doi: 10.1097/gme.0b013e318174f16e.

PMID:
18806686

Supplemental Content

Support Center